Elranatamab clinical trials
Also written Elrexfio and PF-06863135.
How each study uses elranatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elranatamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Aug 2023 · ELREXFIO · BLA 761345 (FDA, Drugs@FDA)
- European Union
- 7 Dec 2023 · Elrexfio · EMEA/H/C/005908 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2025 (10)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 10 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 22
Pfizer (13) · Massachusetts General Hospital (3) · PETHEMA Foundation (2) · M.D. Anderson Cancer Center (2) · SCRI Development Innovations, LLC (2) · Nantes University Hospital (1) · European Myeloma Network B.V. (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
Often tested with
Tested in the same studies.
Lenalidomide (3) · Dexamethasone (2) · Mezigdomide (2) · Daratumumab (2) · Iberdomide (1) · Isatuximab (1) · Autologous Dendritic Cell/Myeloma Fusion Vaccine (1) · Nirogacestat (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 1 in phase 3
Studies that test elranatamab, phase 3 first.
- Aug 2027Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantPhase 3 · Pfizer
- Dec 2026Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaPhase 2 · Ontario Clinical Oncology Group (OCOG)
- Dec 2026ELISA in Relapsed/Refractory MMPhase 2 · Massachusetts General Hospital
- Dec 2026Self-administration of Subcutaneous Elranatamab in the Patients' Homes.Phase 2 · Thomas Lund
- May 2027A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaPhase 1/2 · Celgene
- Jul 2027Use of Elranatamab in Patients With High-risk Smoldering Multiple MyelomaPhase 2 · European Myeloma Network B.V.
- Jul 2027A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)Phase 1 · Genentech, Inc.
- Oct 2027A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot applicable · Institute of Hematology & Blood Diseases Hospital, China
- Nov 2027A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Phase 1 · Pfizer
Studies
Open first, then newest update. How each study uses elranatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 37
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as Elranatamab
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)RecruitingPhase 1Genentech, Inc.NCT05927571Written as Elranatamab
- Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 2PETHEMA FoundationNCT07901868Written as Elranatamab
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingPhase 3PfizerNCT05623020Written as Elranatamab
- HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVRecruitingPhase 1University of Illinois ChicagoNCT07647432Written as Elranatamab (Elra)
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingPhase 4PfizerNCT07881835Written as Elranatamab
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingPhase 3Intergroupe Francophone du MyelomeNCT06918002Written as Elranatamab
- Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Ontario Clinical Oncology Group (OCOG)NCT06421675Written as Elranatamab injection
- ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)RecruitingPhase 2University of MiamiNCT06997081Written as Elranatamab
- A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"RecruitingPhase 2M.D. Anderson Cancer CenterNCT07382739Written as Elranatamab
- ELISA in Relapsed/Refractory MMRecruitingPhase 2Massachusetts General HospitalNCT06832865Written as elranatamab
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple MyelomaRecruitingPhase 2SCRI Development Innovations, LLCNCT07637578Written as Elranatamab
- A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2CelgeneNCT06988488Written as Elranatamab
- Elranatamab in R/R Multiple MyelomaRecruitingPhase 2Massachusetts General HospitalNCT06138275Written as Elranatamab
- A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia ANot yet recruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07788469Written as Elranatamab
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingPhase 3PfizerNCT05020236Written as Elranatamab
- Elranatamab in Patients With Relapsed or Refractory AL AmyloidosisRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT06569147Written as Elranatamab
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06207799Written as Elranatamab
- Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) AmyloidosisNot yet recruitingPhase 2Case Comprehensive Cancer CenterNCT07524634Written as BCMA bispecific
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingPhase 4PfizerNCT06057402Written as Elranatamab
See all 37 studies that test elranatamab →
Given beside what is tested · 7 — elranatamab is usual care or a partner of the new treatment
- AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaRecruitingPhase 1/2AstraZenecaNCT06106945Written as Elranatamab
- A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsRecruitingPhase 1C4 Therapeutics, Inc.NCT07280013Written as Elranatamab
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06121843Written as Elranatamab
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Elranatamab
- A Study of Elranatamab and Cyclophosphamide in People With Multiple MyelomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07454382Written as Elranatamab-bcmm
- Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2YOUNGIL KOHNCT06645678Written as Elranatamab
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaActive, not recruitingPhase 1PfizerNCT05675449Written as Elranatamab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered2
- Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaOct 28, 2026NCT07901868
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsOct 19, 2026NCT07881835
Codes
What other systems call elranatamab · ClinicalTrials.gg INT002170
- MeSH (NLM) C000731940elranatamabOne source NLM
- UNII (FDA) L0HR9A577VELRANATAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q121549012elranatamab (Elrexfio)Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C146860ElranatamabOne source FDA
- DrugBank DB15395One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731940 | elranatamab | One source NLM |
| UNII (FDA) | L0HR9A577V | ELRANATAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q121549012 | elranatamab (Elrexfio) | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C146860 | Elranatamab | One source FDA |
| DrugBank | DB15395 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.